Clinical Trial Update: Phase I/II Trial of S64315 Plus Azacitidine in Acute Myeloid Leukaemia [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II evaluation of S64315 in combination with azacitidine for acute myeloid leukemia has completed, with results posted on 2024-06-06.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• S64315 (S64315)

Snippet

Sponsor: Institut de Recherches Internationales Servier | Conditions: Acute Myeloid Leukaemia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-06-06